$シダラ セラピューティクス(CDTX.US)$ NEWS Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
$シダラ セラピューティクス(CDTX.US)$Cidara Therapeutics To Sell Candidiasis Treatment, Re-acquire Flu Asset WSJ· 4 mins ago Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment. The San Diego-based biotechnology company said Wednesday that it was divesting the treatment, sold under the brand name Rezzayo, t...
$シダラ セラピューティクス(CDTX.US)$Cidara Therapeutics- for Exclusive Global Development, Commercial Rights to Cd388, Johnson & Johnson Got One-Time Upfront Payment of $85 Mln From Co
$シダラ セラピューティクス(CDTX.US)$Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak Dfc Pipeline. Cidara Therapeutics Inc - Mundipharma Agreed to Waive Co's Obligation to Reimburse Mundipharma for a $11.145 Mln Milestone Advance Under Conditions Cidara Therapeutics-Under Deal,Future Royalties & Milestones From Mundipharma,Melinta Therapeutics Previously Payable to Co to Transfer t...
$シダラ セラピューティクス(CDTX.US)$ NEWS Cidara Therapeutics Announces Reverse Stock Split Cidara Therapeutics, a biotechnology company, announced a 1-for-20 reverse stock split of its common stock. The reverse split will be effective on April 23, 2024, with trading on a split-adjusted basis starting on April 24, 2024. This decision was made following a stockholder vote and board approval to enhance the stock's value and reduce the number of outstanding shares.
3
報告
starr67 :
the split takes effect on the 24th not the 23rd?
シダラ セラピューティクスに関するコメント
NEWS
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
Larger Image: tradingview.com...
$シダラ セラピューティクス(CDTX.US)$
Hopefully it'll continue to run tomorrow?
WSJ· 4 mins ago
Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment.
The San Diego-based biotechnology company said Wednesday that it was divesting the treatment, sold under the brand name Rezzayo, t...
Cidara Therapeutics-Under Deal,Future Royalties & Milestones From Mundipharma,Melinta Therapeutics Previously Payable to Co to Transfer t...
NEWS
Cidara Therapeutics Announces Reverse Stock Split
Cidara Therapeutics, a biotechnology company, announced a 1-for-20 reverse stock split of its common stock. The reverse split will be effective on April 23, 2024, with trading on a split-adjusted basis starting on April 24, 2024. This decision was made following a stockholder vote and board approval to enhance the stock's value and reduce the number of outstanding shares.
まだコメントはありません